Navigation Links
RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
Date:12/12/2008

a partial response, six patients had stable disease and one patient had progressive disease. Among the nine patients evaluated in the 30 mg weekly treatment arm, three patients had partial responses, five patients had stable disease and one patient had progressive disease. The critical dose- limiting toxicities occurring in the first cycle of treatment included febrile neutropenia, oral mucositis and confusion occurring in the 5 mg daily, 10 mg daily and 30 mg weekly treatment groups, respectively. The most commonly reported grade 3/4 adverse events (greater than or equal to 10%) suspected of being related to study treatment were neutropenia, lymphopenia, stomatitis, leukopenia, alopecia and anemia.

Study details: abstract #406

An open-label, multicenter Phase I trial evaluated daily RAD001 (2.5 mg, 5 mg and 10 mg) and weekly RAD001 (20 mg, 30 mg, 50 mg and 70 mg) in combination with Navelbine (25 mg/m2 IV over 10-15 min on days 1 and 8 every 21 days) and Herceptin (2 mg/kg IV over 30 min). All patients entering the study had progression on, or shortly after, treatment with Herceptin and all had received prior taxane. The median number of prior chemotherapy regimens was 3 (range: 1-5).

Across treatment arms, there was an overall disease control rate of 62%. Thirty-four heavily pretreated patients were evaluated to date (fifteen patients assigned to 5 mg daily, six to 20 mg weekly, and thirteen to 30 mg weekly). Among the fifteen patients in the 5 mg daily treatment arm, one patient had a complete response, two patients had partial responses, nine patients had stable disease and three patients had progressive disease. Among the six patients in the 20 mg weekly treatment arm, one patient had a partial response, three patients had stable disease and two patients had progressive disease. Among the thirteen patients evaluated in the 30 mg weekly treatment arm, two patients had partial responses, nine pati
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
2. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
3. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
4. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
5. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
6. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
7. New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
8. Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful
9. Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows
10. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
11. Soft Contact Lenses Do Not Lead to Myopic Creep in Children, Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GRAND RAPIDS, Mich. , Jan. 15, 2014 As ... of the flu virus, select Meijer pharmacies in ... and strep throat to eligible patients, enabling Meijer pharmacists to ... under strict protocol set by a physician participating in the ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... condition to the announced tender offer for all of the outstanding ... result of the waiver, the transaction is no longer conditional on ... January 24, 2014 following the currently scheduled expiration time, subject to ...
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... /PRNewswire/ -- PRA International, a leading Clinical Research ... during the 8th Annual Partnerships in Clinical Trials 2009 to ... Trade Centre in Rotterdam, The Netherlands. PRA operational and ... exhibiting at booth number 32. , On 4 November, PRA,s ...
... Shire plc (LSE: SHP, NASDAQ:,SHPGY) the global specialty biopharmaceutical company, announces results for,the three months to September 30, 2009. , , ... ... sales ... Product sales from core products(2) $532 ...
Cached Medicine Technology:PRA International Experts Present a Session at the 8th Annual Partnerships in Clinical Trials 2009 2Shire Continues to Deliver Excellent Growth From Core Products 2Shire Continues to Deliver Excellent Growth From Core Products 3Shire Continues to Deliver Excellent Growth From Core Products 4Shire Continues to Deliver Excellent Growth From Core Products 5Shire Continues to Deliver Excellent Growth From Core Products 6Shire Continues to Deliver Excellent Growth From Core Products 7Shire Continues to Deliver Excellent Growth From Core Products 8Shire Continues to Deliver Excellent Growth From Core Products 9Shire Continues to Deliver Excellent Growth From Core Products 10Shire Continues to Deliver Excellent Growth From Core Products 11Shire Continues to Deliver Excellent Growth From Core Products 12Shire Continues to Deliver Excellent Growth From Core Products 13Shire Continues to Deliver Excellent Growth From Core Products 14Shire Continues to Deliver Excellent Growth From Core Products 15Shire Continues to Deliver Excellent Growth From Core Products 16Shire Continues to Deliver Excellent Growth From Core Products 17Shire Continues to Deliver Excellent Growth From Core Products 18Shire Continues to Deliver Excellent Growth From Core Products 19Shire Continues to Deliver Excellent Growth From Core Products 20Shire Continues to Deliver Excellent Growth From Core Products 21Shire Continues to Deliver Excellent Growth From Core Products 22Shire Continues to Deliver Excellent Growth From Core Products 23Shire Continues to Deliver Excellent Growth From Core Products 24Shire Continues to Deliver Excellent Growth From Core Products 25Shire Continues to Deliver Excellent Growth From Core Products 26Shire Continues to Deliver Excellent Growth From Core Products 27Shire Continues to Deliver Excellent Growth From Core Products 28Shire Continues to Deliver Excellent Growth From Core Products 29Shire Continues to Deliver Excellent Growth From Core Products 30Shire Continues to Deliver Excellent Growth From Core Products 31Shire Continues to Deliver Excellent Growth From Core Products 32Shire Continues to Deliver Excellent Growth From Core Products 33
(Date:4/18/2014)... (April 21, 2014) -- A group of scientists ... and the Sanders-Brown Center on Aging has found ... and neuropsychological function in Parkinson,s disease (PD). ... , the study, which assessed cognitive function in ... the dopamine replacement therapy commonly used to treat ...
(Date:4/18/2014)... memories? How did it make you feel? According to ... experience, such as how sad you were or how ... when you can,t stop thinking about it. , ... context of the memories, rather than how you felt, ... the negative effects of these memories, a new study ...
(Date:4/18/2014)... scientists could lead to potential new treatments for breaking ... , Fibrosis, or scarring, is a hallmark of ... lungs can lead to serious organ damage and, in ... options centers on findings made by Swati Bhattacharyya, PhD, ... that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... SPRING, Md., Sept. 30 The U.S. Food and ... draft guidance for industry on Risk Evaluation and Mitigation ... or biologics. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ... of 2007 (FDAAA) granted the FDA the authority to ...
... , MINNEAPOLIS, Sept. 30 Polaroid ® announces ... support National Breast Cancer Awareness Month beginning October 1st. A ... donated to The Breast Cancer Research Foundation (BCRF). , The ... the third year Polaroid has partnered with BCRF to create awareness ...
... Drug companies are sprinting ahead in a race against the ... the H1N1 influenza virus before cooler weather ushers in the ... issue of Chemical & Engineering News , ACS, weekly ... drugs for flu infections. C&EN senior correspondent Ann Thayer ...
... other types of cardiovascular disease , WEDNESDAY, Sept. 30 ... help protect against heart attacks and other cardiovascular disease, ... guard against the development of heart failure. , Heart ... treatment and lifestyle people are living longer with it. ...
... ... directory gives students insight into acupuncture’s ancient traditions and thriving modern health careers. ... ... health and alternative medicine directory, recently launched The Acupuncture Career and School ...
... ORLEANS, Sept. 30 Pan-American Life Insurance Group (PALIG), ... today that the company has filed a request for ... , "Pan-American Life,s 98-year history and the Group,s ... in this business development decision. Expansion into Costa Rica ...
Cached Medicine News:Health News:FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategies 2Health News:Polaroid(R) and The Breast Cancer Research Foundation(R) Print Pink 2Health News:Study Finds Fish Won't Prevent Heart Failure 2Health News:Study Finds Fish Won't Prevent Heart Failure 3Health News:Acupuncture Career Guide Launches on Natural Healers 2Health News:Acupuncture Career Guide Launches on Natural Healers 3Health News:Pan-American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica; Company Files Request for Authorization 2
... orthosis is designed for the management ... diaphyseal fractures. The lightweight anatomical design ... compression for optimal control of humeral ... both the shoulder and elbow joints. ...
Controls humeral segments through soft tissue compression while allowing for full range of elbow motion...
... RCAI Plantar Fasciitis Night Splint is indicated ... Achilles tendonitis. It is economical and easy ... assist straps for controlled dorsiflexion, limiting nightly ... and Achilles tendon. This feature permits flexibility ...
Comfortably positions the affected foot at 90 to provide continuous and effective stretching of the plantar fascia and Achilles Tendon...
Medicine Products: